Online citations, reference lists, and bibliographies.

Predictive Factors For Irresectability In Advanced Ovarian Cancer

H. Martínez-Said, D. G. Rincón, M. D. de Oca, G. Ruiz, J. L. A. Ponce, C. López-Graniel
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Despite advances in surgical modalities and chemotherapeutic agents, the 5-year survival for patients with advanced ovarian cancer is barely 40–50%. At the moment, optimally cytoreductive primary surgery is the best option for patients with advanced ovarian cancer. Predictive factors of primary optimum reduction surgery have been described based on imaging studies and tumor markers and based on the premise to know a priori the weight and tumor volume, with promising results. A retrospective study was conducted based on the hypothesis that it is feasible to identify those patients not susceptible of undergoing optimum primary cytoreductive surgery. The variables associated with a lesser probability of success in this study are the presence of palpable abdominal tumor on physical examination, the presence of tumor in Douglas' cul-de-sac on vaginal exploration, the presence of ascites in any quantity, elevation of CA-125 above 1000 U/l, and the presence of pulmonary and liver metastases. The success rate for cytoreduction was 62% when none or one of these variables was present and 32% when two or more variables were present.
This paper references
Current initial therapy of stage III and IV ovarian cancer: challenges for managed care.
Schink Jc (1999)
10.1016/0090-8258(92)90107-T
The impact of subspecialty training on the management of advanced ovarian cancer.
S. Eisenkop (1992)
10.1093/annonc/11.suppl_3.131
Optimal treatment for ovarian cancer: taxoids and beyond.
J. Vermorken (2000)
The impact of subspeciality training on the management of advanced ovarian cancer
SM Eisenkop (1992)
10.1200/JCO.1993.11.1.166
Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma.
B. E. Nelson (1993)
10.1200/JCO.1987.5.8.1157
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
J. Neijt (1987)
Primary Cytoreductive Surgery for Epithelial Ovarian Cancer
N. Hacker (1983)
10.1007/BF00399380
Chemotherapy in advanced ovarian cancer
C. J. Rodenburg (1984)
Registro Histopatoló gico de las Neoplasias en México
(1998)
10.1016/0090-8258(90)90042-J
Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study.
K. Bertelsen (1990)
10.1016/0002-9378(79)90824-X
Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute.
J. P. Smith (1979)
The cyclophosphamide, hexamethylamine, 5-fluoracil regimen in the treatment of advanced and recurrent ovarian cancer
JG Posada (1985)
10.1016/S0140-6736(84)90594-4
RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA
J. Neijt (1984)
Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital Tumor Institute
JP Smith (1979)
10.1111/j.1532-5415.1988.tb02362.x
National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making.
A. Brown (1988)
10.1093/ANNONC/11.SUPPL_3.145
Ovarian cancer: optimal chemotherapy in relapsed disease.
P. Conte (2000)
Epidemiology and risk assessment for ovarian cancer.
M. Daly (1998)
10.2214/ajr.165.4.7676985
Ovarian carcinoma: value of CT in predicting success of debulking surgery.
J. Meyer (1995)
Induction chemotherapy in advanced ovarian cancer
LX Barajas (2001)
10.1038/bjc.1994.440
The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma.
S. Kehoe (1994)
Induction chemotherapy in advanced ovarian cancer. Abstracts of 11th International Anticancer Treatment
L X Barajas (2001)
10.1002/1097-0142(19830601)51:11<2024::AID-CNCR2820511111>3.0.CO;2-I
Cis‐platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens
S. Vogl (1983)
10.1200/jco.1988.6.6.983
The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
M. Piver (1988)
10.1016/0090-8258(85)90210-0
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.
P. Conte (1985)
10.1006/GYNO.1998.5213
Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
I. Vergote (1998)
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 vs CP) in advanced ovarian carcinoma
JP Neijt (1987)
10.1006/gyno.1995.0007
Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study.
S. LoCoco (1995)
Cytoreductive surgery for common epithelial tumours of the ovary.
Wharton Jt (1983)
Utility of relaparotomy in patients with ovarian cancer previously operated. Abstracts of 11th International Anticancer Treatment
M Montoya (2001)
10.1016/0020-7292(91)90100-J
Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study
K. Bertelsen (1990)
10.1200/JCO.1986.4.4.515
Prognostic factors in advanced ovarian carcinoma.
J. Redman (1986)
10.1016/0090-8258(84)90040-4
Stage III epithelial ovarian cancer: the role of maximal surgical reduction.
G. Delgado (1984)
10.1016/0020-7292(92)90941-B
Morbidity and Mortality Associated With Primary and Repeat Operations for Ovarian Cancer
P. Venesmaa (1992)
Cytoreductive surgery for common epithelial tumours of the ovary.
J. Wharton (1983)
10.1093/ANNONC/11.SUPPL_3.141
Ovarial cancer: best timing and applications of debulking surgery.
S. Pecorelli (2000)
10.7326/0003-4819-108-2-165
Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
J. Hainsworth (1988)
[Treatment of advanced ovarian cancer].
A. de Gramont (1984)
Review of ovarian cancer at the University of Texas Systems Cancer Center
J P Smith (1979)
Advanced Ovarian Cancer Trialist Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials
(1991)
Prognostic parameters in patients with advanced ovarian malignant tumors.
R. Pohl (1984)
Extensive cytoreductive surgery in advanced ovarian carcinoma.
G. Michel (1997)
10.1200/JCO.1986.4.11.1579
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
K. Louie (1986)
10.1016/0090-8258(85)90141-6
Assessment of morbidity and mortality in primary cytoreductive surgery for advanced ovarian carcinoma.
S. S. Chen (1985)
10.1200/JCO.1989.7.2.223
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
G. Sutton (1989)
10.1002/1098-2388(200007/08)19:1<49::AID-SSU8>3.0.CO;2-Z
Interval debulking surgery: an alternative for primary surgical debulking?
I. Vergote (2000)
Current initial therapy of stage III and IV ovarian cancer: challenges for managed care.
J. Schink (1999)
10.1006/GYNO.2000.5749
The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
D. Chi (2000)
National Institute of Health Issues Consensus Development Conference Statement. Ovarian cancer: screening, treatment and follow-up
(1994)
10.1002/1098-2388(200007/08)19:1<42::AID-SSU7>3.0.CO;2-M
Cytoreductive surgery for advanced stages of ovarian cancer.
J. Dauplat (2000)
10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
Ovarian cancer: epidemiology, biology, and prognostic factors.
C. Holschneider (2000)
10.1136/bmj.303.6807.884
Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
L. Stewart (1991)
10.1016/0090-8258(85)90121-0
The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
J. G. Posada (1985)
FIGO annual report on the results of treatment in gynecological cancer
(1998)
Utility of relaparotomy in patients with ovarian cancer previously operated
M Montoya (2001)
Role of cytoreductive surgical treatment in the management of advanced ovarian cancer.
C. Griffiths (1979)



This paper is referenced by
10.3802/jgo.2011.22.3.183
Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
J. Menczer (2011)
10.1016/J.YGYNO.2008.09.020
Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study.
G. Vorgias (2009)
10.1016/J.YGYNO.2006.11.002
Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction.
R. Bristow (2007)
10.1136/ijgc-00009577-200602001-00053
Elevated CA125 level associated with Meigs' syndrome: case report and review of the literature
Andrés Morán-Mendoza (2005)
10.1016/j.ygyno.2008.04.042
External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score.
J. Brun (2008)
CARCINOMA PRIMARIO DE TROMPA DE FALOPIO. EXPERIENCIA EN EL SERVICIO ONCOLÓGICO HOSPITALARIO IVSS
R. FrancoCalderaroDi (2016)
Elevated Glutaminase in Epithelial Ovarian Cancer Patients Increased the Suboptimal Cytoreduction
G. Winarno (2019)
10.1111/J.1525-1438.2006.00228.X
Elevated CA125 level associated with Meigs' syndrome: case report and review of the literature.
A. Morán-Mendoza (2006)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
Se justifica la ooforectomía profiláctica en histerectomías
L. Díaz (2009)
10.1016/S0123-9015(10)70110-4
Quimioterapia neoadyuvante en cáncer epitelial de ovario en estadios avanzados
Juan Avendano (2010)
10.1093/ANNONC/MDJ981
Multimodal approach to ovarian cancer.
G. Scarfone (2006)
CA-125 como predictor de cirugía citorreductora óptima en cáncer de ovario epitelial
Emilio M. Treviño-Salinas (2014)
10.1002/jso.22053
The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yusuf Yildirim (2012)
10.1111/J.1525-1438.2007.01114.X
Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy
A. Bland (2008)
10.1016/J.YGYNO.2004.01.029
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
D. Chi (2004)
Estudio comparativo entre cirugía primaria y cirugía de intervalo en el estadio iiic del cáncer de ovario
S. Iglesias (2014)
10.1186/1471-2407-9-171
Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy
Jean-Luc Brun (2008)
10.1186/1477-7819-8-11
Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively?
A. Mousavi (2010)
10.1097/01.OGX.0000338468.49565.E4
External Validation of a Laparoscopic-Based Score to Evaluate Resectability of Advanced Ovarian Cancers : Clues for a Simplified Score
J. Brun (2008)
BIOPSIA PERCUTÁNEA DIRIGIDA POR ECOGRAFÍA EN PACIENTES CON TUMORES DE OVARIO
R. Carrillo (2016)
10.1016/j.ygyno.2017.06.008
Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
J. Szender (2017)
A study of the predictive value of morphometric assessments in clinical outcome in ovarian epithelial malignancy
Julia E. Palmer (2007)
10.1016/S0221-0363(09)75663-X
Comment diagnostiquer une masse pelvienne chez la femme
Corinne Balleyguier (2009)
10.1016/J.YGYNO.2006.06.025
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.
R. Bristow (2006)
Semantic Scholar Logo Some data provided by SemanticScholar